



# Global Secondary Progressive Multiple Sclerosis Drug Market Outlook and Growth Opportunities 2026

| Industry            | Published  | Pages | Format |
|---------------------|------------|-------|--------|
| Pharma & Healthcare | 2025-12-19 | 200   | PDF    |

| Single User | Multi User | Enterprise |
|-------------|------------|------------|
| USD 4,250   | USD 6,375  | USD 8,500  |

## Description

The global Secondary Progressive Multiple Sclerosis Drug market was valued at US\$ million in 2026 and is projected to reach US\$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Secondary Progressive Multiple Sclerosis Drug is projected to increase from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Secondary Progressive Multiple Sclerosis Drug is projected to increase from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026-2032.

The Asia Pacific market for Secondary Progressive Multiple Sclerosis Drug is projected to increase from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Secondary Progressive Multiple Sclerosis Drug market is projected to increase from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Secondary Progressive Multiple Sclerosis Drug market include AB Science SA, Actelion Ltd, F. Hoffmann-La Roche Ltd., Genzyme Corporation, Glialogix, Inc., Immune Response BioPharma, Inc., Innate Immunotherapeutics Ltd, Kyorin Pharmaceutical Co., Ltd. and Mallinckrodt Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Secondary Progressive Multiple Sclerosis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Secondary Progressive Multiple Sclerosis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Secondary Progressive Multiple Sclerosis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Secondary Progressive Multiple Sclerosis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

## Secondary Progressive Multiple Sclerosis Drug Segment by Company

AB Science SA  
Actelion Ltd  
F. Hoffmann-La Roche Ltd.  
Genzyme Corporation  
Glialogix, Inc.  
Immune Response BioPharma, Inc.  
Innate Immunotherapeutics Ltd  
Kyorin Pharmaceutical Co., Ltd.  
Mallinckrodt Plc  
MedDay SA  
MedImmune, LLC  
Merck KGaA  
Meta-IQ ApS  
Opexa Therapeutics, Inc.  
Xenetic Biosciences (UK) Limited  
Biogen, Inc.  
Novartis AG

**Secondary Progressive Multiple Sclerosis Drug Segment by Type**

Etomoxir  
Inebilizumab  
IB-MS  
GLX-1112  
DC-TAB  
Others

**Secondary Progressive Multiple Sclerosis Drug Segment by Application**

Hospital  
Clinic  
Others

**Secondary Progressive Multiple Sclerosis Drug Segment by Region**

North America  
United States  
Canada  
Europe  
Germany  
France  
U.K.  
Italy  
Netherlands  
Asia-Pacific  
China  
Japan  
South Korea  
India  
Australia  
China Taiwan  
Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Secondary Progressive Multiple Sclerosis Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Secondary Progressive Multiple Sclerosis Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Secondary Progressive Multiple Sclerosis Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Secondary Progressive Multiple Sclerosis Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

### **Reasons to Buy This Report**

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Secondary Progressive Multiple Sclerosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Secondary Progressive Multiple Sclerosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Secondary Progressive Multiple Sclerosis Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

### **Chapter Outline**

#### **Chapter 1:**

Provides an overview of the Secondary Progressive Multiple Sclerosis Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

#### **Chapter 2:**

Analysis key trends, drivers, challenges, and opportunities within the global Secondary Progressive Multiple Sclerosis Drug industry.

### **Chapter 3:**

Detailed analysis of Secondary Progressive Multiple Sclerosis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

### **Chapter 4:**

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

### **Chapter 5:**

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

### **Chapter 6:**

Sales and value of Secondary Progressive Multiple Sclerosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

### **Chapter 7:**

Sales and value of Secondary Progressive Multiple Sclerosis Drug in country level. It provides sigmate data by type, and by application for each country/region.

### **Chapter 8:**

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

### **Chapter 9:**

Analysis of industrial chain, including the upstream and downstream of the industry.

### **Chapter 10:**

Concluding Insights.

# Table of Contents

---

## 1 Market Overview

- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
  - 1.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032)
  - 1.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume (2021-2032)
  - 1.2.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives

## 2 Secondary Progressive Multiple Sclerosis Drug Market Dynamics

- 2.1 Secondary Progressive Multiple Sclerosis Drug Industry Trends
- 2.2 Secondary Progressive Multiple Sclerosis Drug Industry Drivers
- 2.3 Secondary Progressive Multiple Sclerosis Drug Industry Opportunities and Challenges
- 2.4 Secondary Progressive Multiple Sclerosis Drug Industry Restraints

## 3 Secondary Progressive Multiple Sclerosis Drug Market by Company

- 3.1 Global Secondary Progressive Multiple Sclerosis Drug Company Revenue Ranking in 2025
- 3.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2021-2026)
- 3.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Company (2021-2026)
- 3.4 Global Secondary Progressive Multiple Sclerosis Drug Average Price by Company (2021-2026)
- 3.5 Global Secondary Progressive Multiple Sclerosis Drug Company Ranking (2024-2026)
- 3.6 Global Secondary Progressive Multiple Sclerosis Drug Company Manufacturing Base and Headquarters
- 3.7 Global Secondary Progressive Multiple Sclerosis Drug Company Product Type and Application
- 3.8 Global Secondary Progressive Multiple Sclerosis Drug Company Establishment Date
- 3.9 Market Competitive Analysis
  - 3.9.1 Global Secondary Progressive Multiple Sclerosis Drug Market Concentration Ratio (CR5 and HHI)
  - 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  - 3.9.3 2025 Secondary Progressive Multiple Sclerosis Drug Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion

## 4 Secondary Progressive Multiple Sclerosis Drug Market by Type

- 4.1 Secondary Progressive Multiple Sclerosis Drug Type Introduction
  - 4.1.1 Etomoxir
  - 4.1.2 Inebilizumab
  - 4.1.3 IB-MS
  - 4.1.4 GLX-1112
  - 4.1.5 DC-TAB
  - 4.1.6 Others
- 4.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Type
  - 4.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  - 4.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Type (2021-2032)
  - 4.2.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share by Type (2021-2032)
- 4.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Type
  - 4.3.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Type (2021 VS 2025 VS 2032)
  - 4.3.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Type (2021-2032)

5 Secondary Progressive Multiple Sclerosis Drug Market by Application

5.1 Secondary Progressive Multiple Sclerosis Drug Application Introduction

5.1.1 Hospital

5.1.2 Clinic

5.1.3 Others

5.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Application

5.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Application (2021 VS 2025 VS 2032)

5.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Application (2021-2032)

5.2.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share by Application (2021-2032)

5.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Application

5.3.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Application (2021 VS 2025 VS 2032)

5.3.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Application (2021-2032)

5.3.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application (2021-2032)

6 Secondary Progressive Multiple Sclerosis Drug Regional Sales and Value Analysis

6.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Region: 2021 VS 2025 VS 2032

6.2 Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2021-2032)

6.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Region: 2021-2026

6.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2027-2032)

6.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Region: 2021 VS 2025 VS 2032

6.4 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Region (2021-2032)

6.4.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Region: 2021-2026

6.4.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Region (2027-2032)

6.5 Global Secondary Progressive Multiple Sclerosis Drug Market Price Analysis by Region (2021-2026)

6.6 North America

6.6.1 North America Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032)

6.6.2 North America Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country, 2025 VS 2032

6.7 Europe

6.7.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032)

6.7.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country, 2025 VS 2032

6.8 Asia-Pacific

6.8.1 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032)

6.8.2 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country, 2025 VS 2032

6.9 South America

6.9.1 South America Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032)

6.9.2 South America Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country, 2025 VS 2032

6.10 Middle East & Africa

6.10.1 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032)

6.10.2 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country, 2025 VS 2032

7 Secondary Progressive Multiple Sclerosis Drug Country-level Sales and Value Analysis

7.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Country: 2021 VS 2025 VS 2032

7.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Country: 2021 VS 2025 VS 2032

7.3 Global Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2032)

7.3.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026)

7.3.2 Global Secondary Progressive Multiple Sclerosis Drug Sales by Country (2027-2032)

7.4 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Country (2021-2032)



- 7.4.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Country (2021-2026)
  - 7.4.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Country (2027-2032)
- 7.5 USA
  - 7.5.1 USA Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  - 7.5.2 USA Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  - 7.5.3 USA Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
  - 7.6.1 Canada Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  - 7.6.2 Canada Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  - 7.6.3 Canada Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
  - 7.6.1 Mexico Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  - 7.6.2 Mexico Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  - 7.6.3 Mexico Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
  - 7.8.1 Germany Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  - 7.8.2 Germany Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  - 7.8.3 Germany Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
- 7.9 France
  - 7.9.1 France Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  - 7.9.2 France Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  - 7.9.3 France Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
  - 7.10.1 U.K. Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  - 7.10.2 U.K. Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  - 7.10.3 U.K. Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
  - 7.11.1 Italy Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  - 7.11.2 Italy Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  - 7.11.3 Italy Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
  - 7.12.1 Spain Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  - 7.12.2 Spain Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  - 7.12.3 Spain Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
  - 7.13.1 Russia Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  - 7.13.2 Russia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  - 7.13.3 Russia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
  - 7.14.1 Netherlands Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  - 7.14.2 Netherlands Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  - 7.14.3 Netherlands Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
  - 7.15.1 Nordic Countries Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  - 7.15.2 Nordic Countries Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  - 7.15.3 Nordic Countries Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
- 7.16 China
  - 7.16.1 China Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)

|        |                                                                                                             |
|--------|-------------------------------------------------------------------------------------------------------------|
| 7.16.2 | China Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032                 |
| 7.16.3 | China Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032          |
| 7.17   | Japan                                                                                                       |
| 7.17.1 | Japan Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)                     |
| 7.17.2 | Japan Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032                 |
| 7.17.3 | Japan Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032          |
| 7.18   | South Korea                                                                                                 |
| 7.18.1 | South Korea Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)               |
| 7.18.2 | South Korea Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032           |
| 7.18.3 | South Korea Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032    |
| 7.19   | India                                                                                                       |
| 7.19.1 | India Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)                     |
| 7.19.2 | India Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032                 |
| 7.19.3 | India Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032          |
| 7.20   | Australia                                                                                                   |
| 7.20.1 | Australia Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)                 |
| 7.20.2 | Australia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032             |
| 7.20.3 | Australia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032      |
| 7.21   | Southeast Asia                                                                                              |
| 7.21.1 | Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)            |
| 7.21.2 | Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032        |
| 7.21.3 | Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 |
| 7.22   | Brazil                                                                                                      |
| 7.22.1 | Brazil Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)                    |
| 7.22.2 | Brazil Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032                |
| 7.22.3 | Brazil Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032         |
| 7.23   | Argentina                                                                                                   |
| 7.23.1 | Argentina Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)                 |
| 7.23.2 | Argentina Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032             |
| 7.23.3 | Argentina Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032      |
| 7.24   | Chile                                                                                                       |
| 7.24.1 | Chile Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)                     |
| 7.24.2 | Chile Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032                 |
| 7.24.3 | Chile Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032          |
| 7.25   | Colombia                                                                                                    |
| 7.25.1 | Colombia Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)                  |
| 7.25.2 | Colombia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032              |
| 7.25.3 | Colombia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032       |
| 7.26   | Peru                                                                                                        |
| 7.26.1 | Peru Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)                      |
| 7.26.2 | Peru Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032                  |
| 7.26.3 | Peru Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032           |
| 7.27   | Saudi Arabia                                                                                                |
| 7.27.1 | Saudi Arabia Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)              |
| 7.27.2 | Saudi Arabia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032          |
| 7.27.3 | Saudi Arabia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032   |
| 7.28   | Israel                                                                                                      |
| 7.28.1 | Israel Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)                    |



7.28.2 Israel Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032

7.28.3 Israel Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032

7.29 UAE

7.29.1 UAE Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)

7.29.2 UAE Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032

7.29.3 UAE Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032

7.30 Turkey

7.30.1 Turkey Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)

7.30.2 Turkey Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032

7.30.3 Turkey Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032

7.31 Iran

7.31.1 Iran Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)

7.31.2 Iran Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032

7.31.3 Iran Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032

7.32 Egypt

7.32.1 Egypt Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)

7.32.2 Egypt Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032

7.32.3 Egypt Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032

---

8 Company Profiles

8.1 AB Science SA

8.1.1 AB Science SA Company Information

8.1.2 AB Science SA Business Overview

8.1.3 AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)

8.1.4 AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio

8.1.5 AB Science SA Recent Developments

8.2 Actelion Ltd

8.2.1 Actelion Ltd Company Information

8.2.2 Actelion Ltd Business Overview

8.2.3 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)

8.2.4 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio

8.2.5 Actelion Ltd Recent Developments

8.3 F. Hoffmann-La Roche Ltd.

8.3.1 F. Hoffmann-La Roche Ltd. Company Information

8.3.2 F. Hoffmann-La Roche Ltd. Business Overview

8.3.3 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)

8.3.4 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio

8.3.5 F. Hoffmann-La Roche Ltd. Recent Developments

8.4 Genzyme Corporation

8.4.1 Genzyme Corporation Company Information

8.4.2 Genzyme Corporation Business Overview

8.4.3 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)

8.4.4 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Portfolio

8.4.5 Genzyme Corporation Recent Developments

8.5 Glialogix, Inc.

8.5.1 Glialogix, Inc. Company Information

8.5.2 Glialogix, Inc. Business Overview

8.5.3 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)

8.5.4 Gialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio

8.5.5 Gialogix, Inc. Recent Developments

8.6 Immune Response BioPharma, Inc.

8.6.1 Immune Response BioPharma, Inc. Company Information

8.6.2 Immune Response BioPharma, Inc. Business Overview

8.6.3 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)

8.6.4 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio

8.6.5 Immune Response BioPharma, Inc. Recent Developments

8.7 Innate Immunotherapeutics Ltd

8.7.1 Innate Immunotherapeutics Ltd Company Information

8.7.2 Innate Immunotherapeutics Ltd Business Overview

8.7.3 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)

8.7.4 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio

8.7.5 Innate Immunotherapeutics Ltd Recent Developments

8.8 Kyorin Pharmaceutical Co., Ltd.

8.8.1 Kyorin Pharmaceutical Co., Ltd. Company Information

8.8.2 Kyorin Pharmaceutical Co., Ltd. Business Overview

8.8.3 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)

8.8.4 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio

8.8.5 Kyorin Pharmaceutical Co., Ltd. Recent Developments

8.9 Mallinckrodt Plc

8.9.1 Mallinckrodt Plc Company Information

8.9.2 Mallinckrodt Plc Business Overview

8.9.3 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)

8.9.4 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Portfolio

8.9.5 Mallinckrodt Plc Recent Developments

8.10 MedDay SA

8.10.1 MedDay SA Company Information

8.10.2 MedDay SA Business Overview

8.10.3 MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)

8.10.4 MedDay SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio

8.10.5 MedDay SA Recent Developments

8.11 MedImmune, LLC

8.11.1 MedImmune, LLC Company Information

8.11.2 MedImmune, LLC Business Overview

8.11.3 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)

8.11.4 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product Portfolio

8.11.5 MedImmune, LLC Recent Developments

8.12 Merck KGaA

8.12.1 Merck KGaA Company Information

8.12.2 Merck KGaA Business Overview

8.12.3 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)

8.12.4 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product Portfolio

8.12.5 Merck KGaA Recent Developments

8.13 Meta-IQ ApS

- 8.13.1 Meta-IQ ApS Company Information
- 8.13.2 Meta-IQ ApS Business Overview
- 8.13.3 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
- 8.13.4 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- 8.13.5 Meta-IQ ApS Recent Developments

8.14 Opexa Therapeutics, Inc.

- 8.14.1 Opexa Therapeutics, Inc. Company Information
- 8.14.2 Opexa Therapeutics, Inc. Business Overview
- 8.14.3 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
- 8.14.4 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- 8.14.5 Opexa Therapeutics, Inc. Recent Developments

8.15 Xenetic Biosciences (UK) Limited

- 8.15.1 Xenetic Biosciences (UK) Limited Company Information
- 8.15.2 Xenetic Biosciences (UK) Limited Business Overview
- 8.15.3 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
- 8.15.4 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- 8.15.5 Xenetic Biosciences (UK) Limited Recent Developments

8.16 Biogen, Inc.

- 8.16.1 Biogen, Inc. Company Information
- 8.16.2 Biogen, Inc. Business Overview
- 8.16.3 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
- 8.16.4 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- 8.16.5 Biogen, Inc. Recent Developments

8.17 Novartis AG

- 8.17.1 Novartis AG Company Information
- 8.17.2 Novartis AG Business Overview
- 8.17.3 Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
- 8.17.4 Novartis AG Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- 8.17.5 Novartis AG Recent Developments

---

9 Value Chain and Sales Channels Analysis

9.1 Secondary Progressive Multiple Sclerosis Drug Value Chain Analysis

- 9.1.1 Secondary Progressive Multiple Sclerosis Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Secondary Progressive Multiple Sclerosis Drug Sales Mode & Process

9.2 Secondary Progressive Multiple Sclerosis Drug Sales Channels Analysis

- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Secondary Progressive Multiple Sclerosis Drug Distributors
- 9.2.3 Secondary Progressive Multiple Sclerosis Drug Customers

---

10 Concluding Insights

11 Appendix

- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report

11.5 Data Source

11.5.1 Secondary Sources

11.5.2 Primary Sources

# List of Tables and Figures

## List of Tables:

- Table 1: Secondary Progressive Multiple Sclerosis Drug Industry Trends
- Table 2: Secondary Progressive Multiple Sclerosis Drug Industry Drivers
- Table 3: Secondary Progressive Multiple Sclerosis Drug Industry Opportunities and Challenges
- Table 4: Secondary Progressive Multiple Sclerosis Drug Industry Restraints
- Table 5: Global Secondary Progressive Multiple Sclerosis Drug Revenue by Company (US\$ Million) & (2021-2026)
- Table 6: Global Secondary Progressive Multiple Sclerosis Drug Revenue Share by Company (2021-2026)
- Table 7: Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Company (K Units) & (2021-2026)
- Table 8: Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share by Company (2021-2026)
- Table 9: Global Secondary Progressive Multiple Sclerosis Drug Average Price (US\$/Unit) of Company (2021-2026)
- Table 10: Global Secondary Progressive Multiple Sclerosis Drug Company Ranking, (2024-2026) & (USD Million)
- Table 11: Global Secondary Progressive Multiple Sclerosis Drug Key Company Manufacturing Base & Headquarters
- Table 12: Global Secondary Progressive Multiple Sclerosis Drug Company, Product Type & Application
- Table 13: Global Secondary Progressive Multiple Sclerosis Drug Company Establishment Date
- Table 14: Global Company Market Concentration Ratio (CR5 and HHI)
- Table 15: Global Secondary Progressive Multiple Sclerosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
- Table 16: Mergers & Acquisitions, Expansion
- Table 17: Significant Companies of Etomoxir
- Table 18: Significant Companies of Inebilizumab
- Table 19: Significant Companies of IB-MS
- Table 20: Significant Companies of GLX-1112
- Table 21: Significant Companies of DC-TAB
- Table 22: Significant Companies of Others
- Table 23: Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units)
- Table 24: Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Type (2021-2026) & (K Units)
- Table 25: Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Type (2027-2032) & (K Units)
- Table 26: Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share by Type (2021-2026)
- Table 27: Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share by Type (2027-2032)
- Table 28: Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Type 2021 VS 2025 VS 2032 (US\$ Million)
- Table 29: Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Type (2021-2026) & (US\$ Million)
- Table 30: Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Type (2027-2032) & (US\$ Million)
- Table 31: Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type (2021-2026)
- Table 32: Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type (2027-2032)
- Table 33: Significant Companies of Hospital
- Table 34: Significant Companies of Clinic
- Table 35: Significant Companies of Others
- Table 36: Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units)
- Table 37: Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Application (2021-2026) & (K Units)
- Table 38: Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Application (2027-2032) & (K Units)
- Table 39: Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share by Application (2021-2026)
- Table 40: Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share by Application (2027-2032)
- Table 41: Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Application 2021 VS 2025 VS 2032 (US\$ Million)
- Table 42: Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Application (2021-2026) & (US\$ Million)
- Table 43: Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Application (2027-2032) & (US\$ Million)
- Table 44: Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application (2021-2026)
- Table 45: Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application (2027-2032)
- Table 46: Global Secondary Progressive Multiple Sclerosis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units)
- Table 47: Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2021-2026) & (K Units)
- Table 48: Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2021-2026)
- Table 49: Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2027-2032) & (K Units)
- Table 50: Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2027-2032)
- Table 51: Global Secondary Progressive Multiple Sclerosis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US\$ Million)



- Table 52: Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Region (2021-2026) & (US\$ Million)
- Table 53: Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Region (2021-2026)
- Table 54: Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Region (2027-2032) & (US\$ Million)
- Table 55: Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Region (2027-2032)
- Table 56: Global Secondary Progressive Multiple Sclerosis Drug Market Average Price (US\$/Unit) by Region (2021-2026)
- Table 57: Global Secondary Progressive Multiple Sclerosis Drug Market Average Price (US\$/Unit) by Region (2027-2032)
- Table 58: Global Secondary Progressive Multiple Sclerosis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units)
- Table 59: Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 60: Global Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Units)
- Table 61: Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2021-2026)
- Table 62: Global Secondary Progressive Multiple Sclerosis Drug Sales by Country (2027-2032) & (K Units)
- Table 63: Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2027-2032)
- Table 64: Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Country (2021-2026) & (US\$ Million)
- Table 65: Global Secondary Progressive Multiple Sclerosis Drug Sales Value Market Share by Country (2021-2026)
- Table 66: Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Country (2027-2032) & (US\$ Million)
- Table 67: Global Secondary Progressive Multiple Sclerosis Drug Sales Value Market Share by Country (2027-2032)
- Table 68: AB Science SA Company Information
- Table 69: AB Science SA Business Overview
- Table 70: AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 71: AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- Table 72: AB Science SA Recent Development
- Table 73: Actelion Ltd Company Information
- Table 74: Actelion Ltd Business Overview
- Table 75: Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 76: Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- Table 77: Actelion Ltd Recent Development
- Table 78: F. Hoffmann-La Roche Ltd. Company Information
- Table 79: F. Hoffmann-La Roche Ltd. Business Overview
- Table 80: F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 81: F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- Table 82: F. Hoffmann-La Roche Ltd. Recent Development
- Table 83: Genzyme Corporation Company Information
- Table 84: Genzyme Corporation Business Overview
- Table 85: Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 86: Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- Table 87: Genzyme Corporation Recent Development
- Table 88: Glialogix, Inc. Company Information
- Table 89: Glialogix, Inc. Business Overview
- Table 90: Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 91: Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- Table 92: Glialogix, Inc. Recent Development
- Table 93: Immune Response BioPharma, Inc. Company Information
- Table 94: Immune Response BioPharma, Inc. Business Overview
- Table 95: Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 96: Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- Table 97: Immune Response BioPharma, Inc. Recent Development
- Table 98: Innate Immunotherapeutics Ltd Company Information
- Table 99: Innate Immunotherapeutics Ltd Business Overview
- Table 100: Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 101: Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- Table 102: Innate Immunotherapeutics Ltd Recent Development
- Table 103: Kyorin Pharmaceutical Co., Ltd. Company Information
- Table 104: Kyorin Pharmaceutical Co., Ltd. Business Overview
- Table 105: Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 106: Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- Table 107: Kyorin Pharmaceutical Co., Ltd. Recent Development

- Table 108: Mallinckrodt Plc Company Information
- Table 109: Mallinckrodt Plc Business Overview
- Table 110: Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 111: Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- Table 112: Mallinckrodt Plc Recent Development
- Table 113: MedDay SA Company Information
- Table 114: MedDay SA Business Overview
- Table 115: MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 116: MedDay SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- Table 117: MedDay SA Recent Development
- Table 118: MedImmune, LLC Company Information
- Table 119: MedImmune, LLC Business Overview
- Table 120: MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 121: MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- Table 122: MedImmune, LLC Recent Development
- Table 123: Merck KGaA Company Information
- Table 124: Merck KGaA Business Overview
- Table 125: Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 126: Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- Table 127: Merck KGaA Recent Development
- Table 128: Meta-IQ ApS Company Information
- Table 129: Meta-IQ ApS Business Overview
- Table 130: Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 131: Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- Table 132: Meta-IQ ApS Recent Development
- Table 133: Opexa Therapeutics, Inc. Company Information
- Table 134: Opexa Therapeutics, Inc. Business Overview
- Table 135: Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 136: Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- Table 137: Opexa Therapeutics, Inc. Recent Development
- Table 138: Xenetic Biosciences (UK) Limited Company Information
- Table 139: Xenetic Biosciences (UK) Limited Business Overview
- Table 140: Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 141: Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- Table 142: Xenetic Biosciences (UK) Limited Recent Development
- Table 143: Biogen, Inc. Company Information
- Table 144: Biogen, Inc. Business Overview
- Table 145: Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 146: Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- Table 147: Biogen, Inc. Recent Development
- Table 148: Novartis AG Company Information
- Table 149: Novartis AG Business Overview
- Table 150: Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 151: Novartis AG Secondary Progressive Multiple Sclerosis Drug Product Portfolio
- Table 152: Novartis AG Recent Development
- Table 153: Key Raw Materials
- Table 154: Raw Materials Key Suppliers
- Table 155: Secondary Progressive Multiple Sclerosis Drug Distributors List
- Table 156: Secondary Progressive Multiple Sclerosis Drug Customers List
- Table 157: Research Programs/Design for This Report
- Table 158: Authors List of This Report
- Table 159: Secondary Sources
- Table 160: Primary Sources

**List of Figures:**

- Figure 1: Secondary Progressive Multiple Sclerosis Drug Product Image
- Figure 2: Global Secondary Progressive Multiple Sclerosis Drug Sales Value (US\$ Million), 2021 VS 2025 VS 2032
- Figure 3: Global Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032) & (US\$ Million)
- Figure 4: Global Secondary Progressive Multiple Sclerosis Drug Sales (2021-2032) & (K Units)
- Figure 5: Global Secondary Progressive Multiple Sclerosis Drug Sales Average Price (US\$/Unit) & (2021-2032)
- Figure 6: Global Secondary Progressive Multiple Sclerosis Drug Company Revenue Ranking in 2025 (US\$ Million)
- Figure 7: Global Top 5 and 10 Company Market Share by Revenue in 2025 (US\$ Million)
- Figure 8: Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 9: Etomoxir Image
- Figure 10: Inebilizumab Image
- Figure 11: IB-MS Image
- Figure 12: GLX-1112 Image
- Figure 13: DC-TAB Image
- Figure 14: Others Image
- Figure 15: Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units)
- Figure 16: Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share 2021 VS 2025 VS 2032
- Figure 17: Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share by Type (2021-2032)
- Figure 18: Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 19: Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share 2021 VS 2025 VS 2032
- Figure 20: Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type (2021-2032)
- Figure 21: Hospital Image
- Figure 22: Clinic Image
- Figure 23: Others Image
- Figure 24: Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units)
- Figure 25: Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share 2021 VS 2025 VS 2032
- Figure 26: Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share by Application (2021-2032)
- Figure 27: Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 28: Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share 2021 VS 2025 VS 2032
- Figure 29: Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application (2021-2032)
- Figure 30: Global Secondary Progressive Multiple Sclerosis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units)
- Figure 31: Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region: 2021 VS 2025 VS 2032
- Figure 32: Global Secondary Progressive Multiple Sclerosis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US\$ Million)
- Figure 33: Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Region: 2021 VS 2025 VS 2032
- Figure 34: North America Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032) & (US\$ Million)
- Figure 35: North America Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country (%), 2025 VS 2032
- Figure 36: Europe Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032) & (US\$ Million)
- Figure 37: Europe Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country (%), 2025 VS 2032
- Figure 38: Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032) & (US\$ Million)
- Figure 39: Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country (%), 2025 VS 2032
- Figure 40: South America Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032) & (US\$ Million)
- Figure 41: South America Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country (%), 2025 VS 2032
- Figure 42: Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032) & (US\$ Million)
- Figure 43: Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country (%), 2025 VS 2032
- Figure 44: USA Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US\$ Million)
- Figure 45: USA Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%)
- Figure 46: USA Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%)
- Figure 47: Canada Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US\$ Million)
- Figure 48: Canada Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%)
- Figure 49: Canada Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%)
- Figure 50: Mexico Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: Mexico Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%)
- Figure 52: Mexico Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%)
- Figure 53: Germany Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US\$ Million)
- Figure 54: Germany Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%)
- Figure 55: Germany Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%)
- Figure 56: France Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US\$ Million)
- Figure 57: France Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%)
- Figure 58: France Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%)
- Figure 59: U.K. Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US\$ Million)



- [illegible]

- Figure 117: UAE Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%)
- Figure 118: UAE Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%)
- Figure 119: Turkey Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US\$ Million)
- Figure 120: Turkey Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%)
- Figure 121: Turkey Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%)
- Figure 122: Iran Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US\$ Million)
- Figure 123: Iran Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%)
- Figure 124: Iran Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%)
- Figure 125: Egypt Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US\$ Million)
- Figure 126: Egypt Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%)
- Figure 127: Egypt Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%)
- Figure 128: Secondary Progressive Multiple Sclerosis Drug Value Chain
- Figure 129: Manufacturing Cost Structure
- Figure 130: Secondary Progressive Multiple Sclerosis Drug Sales Mode & Process
- Figure 131: Direct Comparison with Distribution Share
- Figure 132: Distributors Profiles
- Figure 133: Years Considered
- Figure 134: Research Process
- Figure 135: Key Executives Interviewed